A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207)

Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Epacadostat (Primary) ; Carboplatin; Cyclophosphamide; Fluorouracil; Folinic acid; Gemcitabine; Nivolumab; Oxaliplatin; Paclitaxel; Pembrolizumab; Pemetrexed
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ECHO-207
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 23 May 2017 Status changed from not yet recruiting to recruiting.
    • 24 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top